Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas (NOA-16)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02454634 |
Recruitment Status :
Completed
First Posted : May 27, 2015
Last Update Posted : November 7, 2018
|
Sponsor:
National Center for Tumor Diseases, Heidelberg
Collaborators:
University Hospital Heidelberg
German Cancer Research Center
Neuro-Oncology Working Group of the German Cancer Society
Information provided by (Responsible Party):
National Center for Tumor Diseases, Heidelberg
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | September 19, 2017 |
Actual Study Completion Date : | September 19, 2017 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):